Alaunos (TCRT) CEO Holger Weis Receives 4,363 Shares

What Happened

• Holger Weis, CEO of Alaunos Therapeutics (TCRT), was issued 4,363 shares of common stock on Aug 6, 2026 at $2.01 per share, a total value of $8,770. The transaction is reported as an award/acquisition (code A).

Key Details

• Transaction date: 2026-08-06
• Price per share: $2.01; Total value: $8,770
• Shares acquired: 4,363
• Transaction type/code: Award/issuance (A)
• Footnote: F1 — shares were issued in lieu of net salary
• Shares owned after transaction: not specified in the filing
• Filing date: 2026-08-11 — the report was submitted five days after the transaction (outside the typical 2-business-day Form 4 window), suggesting a late filing

Context

• These shares were issued as compensation rather than purchased on the open market, so the transaction reflects executive pay mechanics rather than a market buy or sale. Such awards are common and do not, by themselves, imply a change in the CEO’s view of the company.